BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: The BIM deletion polymorphism appeared to occur at a frequency of 12.3% individuals only in East Asia, and showed an inferior response to tyrosine kinas inhibitors (TKIs) when compared to those without the deletion in CML patients [25].